We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MRCY:NASDAQMercury Systems Inc Analysis

Data as of 2026-04-18 - not real-time

$84.05

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Mercury Systems (MRCY) is trading around $84, comfortably above its 20‑day SMA of $78 and the 200‑day SMA of $74, but still below the near‑term resistance of $88. The MACD histogram is positive and the signal line is bearish, yielding a bullish MACD reading, while the RSI sits at 56, indicating neutral momentum. Recent contract wins with L3Harris for satellite data recorders and missile‑defense support provide a fresh catalyst, and the market sentiment is in the “Extreme Greed” zone (fear‑greed index 90).
Fundamentally, the company remains overvalued – the DCF fair‑value estimate of roughly $25 is far below the current price, and the forward P/E of 56 dwarfs the industry average of 31. Margins are still negative, debt‑to‑equity is high, and volatility is elevated at nearly 50% with a beta around 1.7, suggesting heightened risk despite solid cash flow generation. The blend of strong defense‑spending tailwinds and valuation concerns points to a cautious but opportunistic stance.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Recent L3Harris contract win adding near‑term revenue upside
  • Bullish MACD crossover and price above 20‑day SMA
  • Support level comfortably above $69 with room to test resistance

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Defense‑spending tailwinds supporting revenue growth
  • Persistent overvaluation relative to DCF fair value
  • Improving cash flow but continued negative earnings and high debt

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant valuation gap to fair value discourages long‑run upside
  • High beta and volatility increase exposure to market swings
  • Potential for sustained defense contracts if execution improves

Key Metrics & Analysis

Financial Health

Revenue Growth4.40%
Profit Margin-3.23%
P/E Ratio56.1
ROE-2.08%
ROA-0.01%
Debt/Equity46.52
P/B Ratio3.4
Op. Cash Flow$121.8M
Free Cash Flow$111.8M
Industry P/E31.3

Technical Analysis

TrendNeutral
RSI56.7
Support$69.06
Resistance$88.06
MA 20$78.10
MA 50$82.15
MA 200$74.82
MACDBullish
VolumeDecreasing
Fear & Greed Index90.21

Valuation

Fair Value$24.63
Target Price$96.88
Upside/Downside15.26%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.67
Volatility49.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.